Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 6:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–47 of 47 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: piperacillin-tazobactam Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Two Different Antibiotics Versus One Antibiotic for Pediatric Perforated Appendicitis

NCT03289351
View directory record Official record
Conditions
Perforated Appendicitis, Postoperative Infection
Interventions
Piperacillin, Tazobactam Drug Combination
Drug
Lead sponsor
Phoenix Children's Hospital
Other
Eligibility
Up to 18 Years
Enrollment
162 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
2
States / cities
Phoenix, Arizona • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 12, 2024 · Synced Oct 3, 2026, 6:56 PM EDT
Terminated Phase 4 Interventional Results available

Effects of Therapy With Sulfamylon® 5% Topical Solution Compared to a Historical Control Group

NCT00634166
View directory record Official record
Conditions
Burns
Interventions
Sulfamylon® For 5 % Topical Solution, Topical Antimicrobial/Antifungal Medications
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
3 Months and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
9
States / cities
Mobile, Alabama • Redlands, California • Gainesville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2022 · Synced Oct 3, 2026, 6:56 PM EDT
Completed No phase listed Observational

Antimicrobial PK in Infants With Suspected or Confirmed Infection

NCT00491426
View directory record Official record
Conditions
Infection
Interventions
Ampicillin, Metronidazole, Piperacillin/Tazobactam, Acyclovir, Amphotericin B, Ambisome, Anidulafungin, Caspofungin
Drug
Lead sponsor
Duke University
Other
Eligibility
Up to 120 Days
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
6
States / cities
La Jolla, California • Washington D.C., District of Columbia • Louisville, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2012 · Synced Oct 3, 2026, 6:56 PM EDT
Completed Phase 3 Interventional

Study Comparing the Safety and Efficacy of Piperacillin/Tazobactam to Cefepime in Patients With Hematologic Malignancy or Lymphoma

NCT00044759
View directory record Official record
Conditions
Hematologic Neoplasms
Interventions
Piperacillin/Tazobactam (Tazocin)
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2003
U.S. locations
31
States / cities
Little Rock, Arkansas • Los Angeles, California • Denver, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2007 · Synced Oct 3, 2026, 6:56 PM EDT
Recruiting Not applicable Interventional

Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial

NCT06080698
View directory record Official record
Conditions
Gram-negative Bacteremia
Interventions
Intravenous Antibiotics, Oral Antibiotics
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
1,030 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
11
States / cities
San Francisco, California • Denver, Colorado • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 3, 2026, 6:56 PM EDT
Completed Phase 2 Interventional Results available

PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN

NCT04983901
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Imipenem/Cilastatin/Relebactam, Cefepime, Meropenem, Piperacillin-Tazobactam, Vancomycin, Daptomycin, Linezolid
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 3, 2026, 6:56 PM EDT
Recruiting Phase 4 Interventional

The Vancomycin Piperacillin/Tazobactam (VPT) Patient Safety Trial (VPS)

NCT07556107
View directory record Official record
Conditions
Infection, Acute Kidney Injury, Sepsis
Interventions
Piperacillin + Tazobactam, meropenem
Drug
Lead sponsor
Bassett Healthcare
Other
Eligibility
18 Years and older
Enrollment
852 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Cooperstown, New York • Winston-Salem, North Carolina • Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 3, 2026, 6:56 PM EDT
Terminated Phase 2 Interventional Results available

eXtended Antibiotic Prophylaxis for Intermediate- and High-risk Glands After Pancreatoduodenectomy to Reduce CR-POPF

NCT05753735
View directory record Official record
Conditions
Pancreatic Fistula
Interventions
Piperacillin/Tazobactam, Amoxicillin/ Clavulanic acid
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Oct 3, 2026, 6:56 PM EDT
Withdrawn Phase 2 Interventional

Fecal Transplant +/- Gut Decontamination in Preventing Acute Graft Versus Host Disease in Patients Given Broad-Spectrum Antibiotics

NCT03862079
View directory record Official record
Conditions
Graft-versus-host Disease Prevention
Interventions
Best Practice, Fecal Microbiota Transplantation, Nystatin, Piperacillin-Tazobactam
Other · Procedure · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 3, 2026, 6:56 PM EDT
Terminated Phase 3 Interventional Results available

Study of Intravenous Ceftolozane/Tazobactam Compared to Piperacillin/Tazobactam in Ventilator-Associated Pneumonia

NCT01853982
View directory record Official record
Conditions
Ventilator-Associated Pneumonia (VAP)
Interventions
Ceftolozane/Tazobactam, Piperacillin/Tazobactam
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
11
States / cities
Jacksonville, Florida • Chicago, Illinois • Baltimore, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 3, 2026, 6:56 PM EDT
Completed Not applicable Interventional Results available

PK/PD of High Dose Pip/Tazo in Obese Patients

NCT01923363
View directory record Official record
Conditions
Obesity
Interventions
Piperacillin/Tazobactam Standard Dose to High Dose
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 89 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Oct 26, 2018 · Synced Oct 3, 2026, 6:56 PM EDT
Recruiting No phase listed Observational

Shorter Versus Extended Course of Antibiotic Therapy for Necrotizing Soft Tissue Infections

NCT06002607
View directory record Official record
Conditions
Necrotizing Soft Tissue Infection
Interventions
Antibiotic duration (short course), Antibiotic duration (extended course)
Other
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 3, 2026, 6:56 PM EDT
Terminated Phase 4 Interventional Results available

Continuous Infusion Piperacillin-tazobactam for the Treatment of Cystic Fibrosis

NCT01694069
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Piperacillin-tazobactam combination product
Drug
Lead sponsor
West Virginia University
Other
Eligibility
8 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Feb 1, 2022 · Synced Oct 3, 2026, 6:56 PM EDT
Completed No phase listed Observational

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

NCT01431326
View directory record Official record
Conditions
Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions
The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
Up to 21 Years
Enrollment
3,520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
43
States / cities
Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Oct 3, 2026, 6:56 PM EDT
Recruiting Phase 4 Interventional

A Pragmatic Clinical Trial Comparing the Risk of Acute Kidney Injury During Treatment With Vancomycin and Piperacillin-Tazobactam vs. Vancomycin and Cefepime in Hospitalized Patients

NCT06954129
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Vancomycin, Piperacillin-tazobactam, Cefepime
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 3, 2026, 6:56 PM EDT
Completed Not applicable Interventional

Standard vs. Biofilm Susceptibility Testing in Cystic Fibrosis (CF)

NCT00153634
View directory record Official record
Conditions
Cystic Fibrosis, Chronic Bronchitis
Interventions
IV amikacin, PO azithromycin, IV ceftazidime, PO ciprofloxacin, IV meropenem, IV piperacillin-tazobactam, IV ticarcillin-clavulanate, IV tobramycin
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
14 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
8
States / cities
Iowa City, Iowa • St Louis, Missouri • Cincinnati, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2008 · Synced Oct 3, 2026, 6:56 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy of Oral Antibiotic Therapy Compared to Intravenous Antibiotic Therapy for Osteomyelitis

NCT02168816
View directory record Official record
Conditions
Osteomyelitis
Interventions
Intravenous Antibacterial Agent, Oral Antibacterial Agent
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 19, 2018 · Synced Oct 3, 2026, 6:56 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety and Efficacy of ZTI-01 (IV Fosfomycin) vs Piperacillin/Tazobactam for Treatment cUTI/AP Infections

NCT02753946
View directory record Official record
Conditions
Urinary Tract Infection Symptomatic, Acute Pyelonephritis, Urinary Tract Infection Complicated
Interventions
ZTI-01, Piperacillin-tazobactam
Drug
Lead sponsor
Nabriva Therapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
6
States / cities
Pensacola, Florida • Augusta, Georgia • Columbus, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2019 · Synced Oct 3, 2026, 6:56 PM EDT
Completed Not applicable Interventional

Initial Antibiotics and Delayed Appendectomy for Acute Appendicitis

NCT01697059
View directory record Official record
Conditions
Acute Appendicitis
Interventions
Piperacillin + Amoxicillin
Drug
Lead sponsor
Rhode Island Hospital
Other
Eligibility
5 Years to 18 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 6, 2015 · Synced Oct 3, 2026, 6:56 PM EDT
Completed Phase 3 Interventional

Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count

NCT00003805
View directory record Official record
Conditions
Bone Marrow Suppression, Fever, Sweats, and Hot Flashes, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
piperacillin sodium, piperacillin-tazobactam, tazobactam sodium, vancomycin
Drug
Lead sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Network
Eligibility
2 Years and older
Enrollment
859 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
2
States / cities
Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 24, 2012 · Synced Oct 3, 2026, 6:56 PM EDT
Active, not recruiting Phase 2 Interventional

RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)

NCT04514653
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration (nAMD)
Interventions
Ranibizumab, ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, ABBV-RGX-314 Dose 3, Local Steroid, Topical Steroid, ABBV-RGX-314 Dose 4
Biological · Genetic · Drug
Lead sponsor
AbbVie
Industry
Eligibility
50 Years to 89 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
18
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 3, 2026, 6:56 PM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetics and Safety of Piperacillin-tazobactam in Neonates

NCT00873327
View directory record Official record
Conditions
Sepsis
Interventions
piperacillin-tazobactam
Drug
Lead sponsor
Phillip Brian Smith
Other
Eligibility
Up to 60 Days
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
4
States / cities
Indianapolis, Indiana • Wichita, Kansas • Kansas City, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2018 · Synced Oct 3, 2026, 6:56 PM EDT
Terminated No phase listed Observational

Pharmacokinetics of Antibiotics During Extracorporeal Membrane Oxygenation (ECMO) Support

NCT03922451
View directory record Official record
Conditions
Drug Effect
Interventions
piperacillin-tazobactam, Cefazolin
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 18 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Oct 3, 2026, 6:56 PM EDT